Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational StudyReport as inadecuate

Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study - Download this document for free, or read online. Document in PDF available to download.

The Patient - Patient-Centered Outcomes Research

, Volume 9, Issue 1, pp 35–46

First Online: 07 November 2015DOI: 10.1007-s40271-015-0151-y

Cite this article as: Serpell, M., Tripathi, S., Scherzinger, S. et al. Patient 2016 9: 35. doi:10.1007-s40271-015-0151-y


BackgroundOpioids provide effective analgesia for moderate-to-severe, chronic pain. Transdermal buprenorphine TDB is available in the UK as weekly, lower-dose 5–20 μg-h patches and twice-weekly, higher dose 35–70 μg-h patches. This prospective, observational, multicenter study of patients with various chronic pain conditions assessed the safety, perceptions, and discontinuation of treatment with TDB in a real-world, non-interventional setting study ID: NCT01225861.

MethodsPatients aged ≥18 years who were already receiving or initiating treatment with TDB were recruited in the UK during routine clinical visits and were followed for 6 visits or 9 months whichever came first. Self-reported treatment adherence, patient satisfaction, and safety data were collected at each study visit.

ResultsOf 465 patients, 272 were already receiving 7-day TDB at the study start TDB experienced, 146 were TDB naïve, and 47 were prescribed twice-weekly TDB. Most patients were female 72.9 % and overweight-obese body mass index ≥25: 75.3 %. The median age was 67 years, and the mean duration of pain was 11.1 years. Arthritis-other musculoskeletal disorders 39.6 % were the most common causes of pain. Mild adverse events were commonly reported. Skin irritations, which were most frequent in 7-day TDB-experienced patients 45.6 %, rarely resulted in treatment discontinuation 8.8 %. Nearly all patients used TDB in accordance with treatment recommendations. Most patients reported that TDB was ‘effective’-‘very effective’ at relieving pain and were ‘satisfied’-‘very satisfied’ with TDB therapy.

ConclusionIn everyday clinical practice, TDB was well tolerated and patients were satisfied with their therapy. Self-reported adherence to TDB was very high, and adverse events rarely resulted in treatment discontinuation. Opportunities were identified to limit common adverse events associated with TDB.

Electronic supplementary materialThe online version of this article doi:10.1007-s40271-015-0151-y contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Mick Serpell - Shiva Tripathi - Sabine Scherzinger - Sònia Rojas-Farreras - Alexander Oksche - Margaret Wilson


Related documents